Physician profile
Randall Gale
NPI 1770843724
$4,007.98
in general payments reported to CMS, 2019-2025
28 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $905 · 2021: $886 · 2022: $362 · 2023: $354 · 2024: $504 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $569.46 | 2020-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $518.80 | 2019-2025 | |
| Boston Scientific Corporation | $451.87 | 2020-2025 | Watchman Flx, General - Therapies |
| Artivion, INC. | $288.07 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $265.27 | 2019-2024 | |
| Medtronic Vascular, INC. | $228.24 | 2019-2020 | |
| Cardiovascular Systems INC. | $168.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $157.61 | 2019-2023 | Farxiga |
| Abbott Laboratories | $157.41 | 2021-2023 | Confirm Rx |
| Penumbra, INC. | $136.70 | 2020 | |
| Edwards Lifesciences Corporation | $132.31 | 2024 | Konect Resilia |
| Amgen INC. | $131.74 | 2019-2025 | Repatha, Repatha |
| Biosense Webster, INC. | $124.78 | 2019 | |
| Merck Sharp & Dohme LLC | $111.08 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $105.04 | 2019-2023 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $84.62 | 2019-2025 | |
| Chiesi USA, INC. | $62.18 | 2020-2021 | |
| Cleerly, INC. | $60.70 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Sanofi-Aventis U.S. LLC | $54.90 | 2019-2021 | |
| Astellas Pharma US INC | $42.57 | 2019-2021 | |
| Itamar Medical INC | $32.09 | 2022 | |
| Heartflow, INC. | $25.43 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.84 | 2021 | |
| Biotronik INC. | $18.08 | 2020 | |
| Medtronic, INC. | $14.36 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $14.14 | 2021 | |
| Philips North America LLC | $13.72 | 2023 | |
| Esperion Therapeutics, INC. | $13.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Gale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.